



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12N 15/19, C07H 21/04, 21/02 C12N 5/02, 5/06, 5/08	A1	(11) International Publication Number: WO 90/08188 (43) International Publication Date: 26 July 1990 (26.07.90)
(21) International Application Number: PCT/AU90/00001 (22) International Filing Date: 9 January 1990 (09.01.90) (30) Priority data: PJ 2220 10 January 1989 (10.01.89) AU PJ 2706 13 February 1989 (13.02.89) AU PJ 4860 23 June 1989 (23.06.89) AU (71) Applicant (for all designated States except US): AMRAD CORPORATION LIMITED [AU/AU]; 17-27 Cotham Road, Kew, VIC 3101 (AU). (72) Inventors; and (75) Inventors/Applicants (for US only) : GOUGH, Nicholas, Martin [GB/AU]; 20 Rangeview Grove, North Balwyn, VIC 3104 (AU). WILLSON, Tracey, Ann [AU/AU]; 26 Fortuna Avenue, North Balwyn, VIC 3104 (AU). SEAMARK, Robert, Frederick [AU/AU]; 34 Union Street, Beulah Park, S.A. 5067 (AU).		(74) Agents: CORBETT, Terence, G. et al.; Davies & Collison, 1 Little Collins Street, Melbourne, VIC 3000 (AU). (81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US. Published <i>With international search report.</i>
(54) Title: LEUKAEMIA INHIBITORY FACTOR FROM LIVESTOCK SPECIES AND USE THEREOF TO ENHANCE IMPLANTATION AND DEVELOPMENT OF EMBRYONIC CELLS (57) Abstract <p>The present invention relates generally to the isolation of leukaemia inhibitory factor (LIF) genes from livestock species, the expression of said genes in recombinant vectors and the isolation of the recombinant LIF molecules and the use of livestock species LIF to enhance the <i>in vitro</i> development of an embryo to the implantation stage.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Faso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	HU	Hungary	NO	Norway
BJ	Benin	IT	Italy	RO	Romania
BR	Brazil	JP	Japan	SD	Sudan
CA	Canada	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LI	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark				

- 1 -

LEUKAEMIA INHIBITORY FACTOR FROM LIVESTOCK SPECIES
AND USE THEREOF TO ENHANCE IMPLANTATION AND
DEVELOPMENT OF EMBRYONIC CELLS

5

The present invention relates generally to leukaemia inhibitory factor (LIF) from livestock species. More particularly, the present invention relates to the identification, cloning and structural characterisation
10 of genes encoding LIF from livestock species. The present invention also relates to the use of LIF from livestock species in the enhancement of development of mammalian embryos and in maintaining ES cell lines in vitro.

15

LIF is a protein that has previously been cloned, produced and purified, in large quantities in purified recombinant form from both E.coli and yeast cells (International Patent Application No. PCT/AU88/00093.)

20 LIF has been defined as a factor, the properties of which include:

1. the ability to suppress the proliferation of myeloid leukaemic cells such as M1 cells, with associated
25 differentiation of the leukaemic cells; and
2. the ability to compete with a molecule having the defined sequence of murine LIF or human LIF (defined in International Patent Application No.
30 PCT/AU88/00093) for binding to specific cellular receptors on M1 cells or murine or human macrophages. In addition to the biological properties previously disclosed for murine and human LIF, LIF has been found to have the following
35 additional properties:

- 2 -

- 5 (a) it maintains in vitro in the absence of feeder cells, the pluripotential phenotype of murine embryonic stem (ES) cell lines: D3 and EK-cs4 (derived from strain 129/SV blastocysts) and CBL63 and HD5 (derived from C57BL/6 blastocysts) as disclosed in International Application No. PCT/AU89/00330;
- 10 (b) it allows the aforementioned ES cell lines, after passage in vitro in the presence of LIF, to contribute to the tissues of chimaeric mice when re-introduced into the embryonic environment;
- 15 (c) it demonstrates selective binding to high affinity receptors on murine ES (EK-cs1 and D3) and embryonic carcinoma (EC) (PCC3-3A, F9, PC13, P19 and MG2) cells; and
- 20 (d) specific binding of ^{125}I -LIF to high affinity receptors is not in competition with insulin, IGF-I, IGF-II, acidic and basic FGF, TGF β , TNF α , TNF β , NGF, PDGF, EGF, IL-1, IL-2, IL-4, GM-CSF, G-CSF, Multi-CSF nor erythropoietin, but is in
- 25 competition with murine and human LIF.

Accordingly, LIF is a potent hormone having utility in the general area of in vitro embryology, such as in maintaining ES cell lines and increasing the efficiency of embryo transfer and thus has important applications in the livestock industry. This is particularly apparent in the use of ES cells to provide a route for the generation of transgenic animals.

35 A major difficulty associated with present in vitro fertilisation (IVF) and embryo transfer (ET) programmes, particularly in humans, is the low success rate

- 3 -

"achieved" on implantation of fertilised embryos.
Currently, in human IVF programmes, the implantation rate may be as low as 10%, leading to the present practice of using up to four fertilised embryos in each treatment
5 which, in turn, leads occasionally to multiple births. Accordingly, there is a need to improve the implantation rate in human IVF programmes. Similarly, in IVF and ET treatments in domestic animals such as sheep, cattle, pigs and goats, it is highly desirable for economic
10 reasons to have as high an implantation rate as possible so as to reduce the numbers of fertilised embryos lost and unsuccessful treatment procedures performed.

In the development of a mammalian embryo, the
15 fertilised egg passes through a number of stages including the morula and the blastocysts stages. In the blastocyst stage, the cells form an outer cell layer known as the trophectoderm (which is the precursor of the placenta) as well as an inner cells mass (from which the
20 whole of the embryo proper is derived). The blastocyst is surrounded by the zona pellucida, which is subsequently lost when the blastocyst "hatches". The cells of the trophectoderm are then able to come into close contact with the wall of the uterus in the
25 implantation stage. Prior to formation of the embryo proper by the inner cell mass by gastrulation, the whole cell mass may be referred to as "pre-embryo".

Although LIF from one species may be effective, for
30 example in maintaining ES cell lines from a different or heterologous species, it may be preferable to develop homologous systems employing LIF and ES cell lines derived from the same species. It has now been found, in accordance with the present invention, that murine LIF
35 DNA can be used to identify the LIF gene from a wide range of mammalian genomes and to clone the gene encoding LIF from livestock species such as pigs and sheep and

- 4 -

hence, provide a source of LIF for use in the development of a variety of in vitro embryogenic procedures, such as ES cell lines and embryo transfer in livestock species.

- 5 Furthermore, it has also been found that when LIF is included in an in vitro embryo culture medium, the hatching process is enhanced leading to an increased number of embryos completing the development stage by undergoing developmental changes associated with
- 10 implantation. As a result, the implantation rate for IVF and ET programmes can be significantly improved by the use of LIF in the in vitro embryo culture medium.

- Accordingly, one aspect of the present invention
- 15 relates to the LIF gene from any livestock species which can be detected by cross-hybridization with a nucleotide probe to murine LIF. That is, a first nucleic acid molecule, encoding a livestock species leukaemia inhibitory factor, comprising a nucleotide sequence
- 20 capable of hybridizing to a second nucleic acid molecule which encodes murine leukaemia inhibitory factor or part thereof.

- A "nucleotide probe" as used herein means a DNA or RNA sequence or any combination thereof capable of
- 25 detecting complementary sequences by hybridization techniques such as, but not limited to, Southern or Northern blotting or colony hybridization. The probe may comprise a small number of nucleotides (eg. 6-20) or may be the entire gene or part or parts of a gene. The probe
- 30 may be labelled with a detectable signal (eg. radioactive isotope).

- By "nucleic acid" is meant a polymer of four or more nucleotides in which the 3' position of one nucleotide
- 35 sugar is linked to the 5' position of the next nucleotide by a phosphodiester bridge. The nucleic acid contemplated herein may be linear or circular, single or

- 5 -

double stranded DNA or RNA.

"Livestock species" is used herein in its most general sense encompassing, but not limited to, sheep,
5 cows, pigs, horses, donkeys and the like. Even more preferably, the livestock species is sheep or pig.

By "hybridizing" is meant the ability to form a double stranded third nucleic acid by the formation of
10 base pairs between single strands of the first and second nucleic acid under appropriate conditions of stringency. The stringency conditions employed will depend on the relative homology between the relevant strands of the first and second nucleic acid molecules. Convenient
15 conditions for stringency can be found in Maniatis et al. (1982) or by reference to the non-limiting examples of the present specification.

Accordingly, where the nucleic acids are double
20 stranded molecules, the present invention relates to a first nucleic acid encoding part or parts of livestock species leukaemia inhibitory factor comprising on one strand thereof a nucleotide sequence capable of being hybridized to by a strand of a second nucleic acid
25 encoding part or parts of murine LIF.

Although the present invention is exemplified by the second nucleic acid encoding murine LIF or parts thereof, it is possible that a different nucleic acid encoding
30 non-murine LIF but which is capable of hybridizing to murine-LIF nucleic acid could be used. The use of non-murine LIF-encoding second nucleic acid is, therefore, still encompassed by the present invention provided said non-murine LIF-encoding nucleic acid is capable of being
35 hybridized to by the said second nucleic acid encoding murin LIF or parts thereof.

- 6 -

The present invention extends to nucleic acids encoding full length LIF molecules or to part or parts of LIF molecules. Accordingly, the nucleic acids may represent the full coding sequence of mammalian LIF or
5 carry single or multiple nucleotide additions, deletions and/or substitutions or may represent just a portion of the LIF molecule, for example an N-terminal or C-terminal portion. Accordingly, "parts" of a LIF molecule includes any one or more contiguous series of amino acids
10 contained within a LIF molecule and further includes natural, chemical and/or recombinant derivatives.

Another aspect of the present invention relates to a recombinant DNA molecule containing the nucleotide
15 sequence encoding LIF from a livestock species or substantially similar analogues thereof, either completely or in part, in a form in which said nucleotide sequence is able to direct the synthesis and production of said LIF, either completely or in part. This aspect
20 of the invention also extends to cloning vectors such as plasmids and expression vectors and host cells having such recombinant DNA molecules inserted therein. Furthermore, the invention also extends to synthetic livestock LIF, either complete or in part, or
25 substantially similar analogues thereof, produced by expression of such recombinant DNA molecules.

Accordingly, this aspect of the present invention relates to recombinant DNA or RNA molecules comprising
30 the first nucleic acid defined above operably linked to one or more regulatory regions such that in the appropriate host and under the requisite conditions, the first nucleic acid will be transcribed and translated into a recombinant LIF product or derivative or part
35 thereof. The recombinant molecule will further comprise a replication region appropriate for the intended host or may comprise more than one replication region if more

- 7 -

than one host is used. Vectors and suitable hosts are known to those skilled in the art and are discussed in the non-limited examples herein, in PCT/AU88/00093 and in Maniatis et al. (1982).

5

The present invention, therefore, extends to recombinant livestock LIF, and preferably, but not limited to, ovine and porcine LIF or derivatives or parts thereof. Such derivatives or parts thereof are discussed above but include single or multiple amino acid substitutions, deletions and/or additions to or in the natural or synthetic livestock LIF molecule. Conditions for preparing recombinant LIF are disclosed in PCT/AU88/00093 although variations and/or modifications to these conditions may vary depending on the host cell used. Any such variations and/or modifications are within the scope of the subject invention. The host cells may be eukaryotic (eg yeast, mammalian, plant etc.) cells or prokaryotic (eg Escherichia coli, Bacillus sp, Pseudomonas sp etc.).

Yet another aspect of the present invention provides a source of recombinant livestock LIF for use in in vitro embryology. Accordingly, the present invention contemplates a method for maintaining ES cell lines in in vitro culture while retaining a pluripotential phenotype which method comprises contacting said ES cell lines with an ES cell line maintaining effective amount of livestock species LIF for sufficient time and under appropriate conditions.

Still yet another aspect of the present invention relates to a method for enhancing the in vitro development of a mammalian embryo to the implantation stage, which method comprises the step of culturing the embryo in vitro in a culture medium containing an effective amount of mammalian LIF.

- 8 -

Preferably, pre-embryos are allowed to develop to the stage of formation of the blastocyst (post-hatching embryos) before LIF is included in the culture medium as LIF has been found to enhance the hatching process leading to an increased number of embryos completing the developmental stage. As is demonstrated below, however, the inclusion of LIF in the culture medium prior to the formation of the blastocyst, or both prior to and following blastocyst formation, also increases the number of pre-embryos completing the developmental stage by undergoing development changes associated with implantation. As a result, the implantation rate for IVF and ET programmes can be significantly improved by use of LIF in the in vitro culture medium.

"Mammalian embryos" is used in its broadest sense encompassing human, ruminant and other livestock animals. It will be appreciated that while the subject invention is exemplified herein by the development of murine embryos in vitro, the present invention extends to the use of LIF in the development of embryos of other species including humans, ruminants and animals such as sheep, cattle, horses, donkeys, goats and the like.

The present invention, also extends to a method for in vitro fertilisation and subsequent implantation of a mammalian embryo which is characterised in that the embryo is cultured in vitro in a culture medium containing an effective amount of mammalian LIF prior to implantation.

"Mammalian LIF" encompasses human, murine, ruminant and other or livestock LIF such as from sheep, pigs, cows, goats, donkeys and horses and the like.

- 9 -

In the figures:

FIGURE 1 relates to Example 1. The identification of LIF gene homologues in DNA from a variety of mammalian species by cross-hybridization with a murine cDNA probe.

FIGURE 2 shows the nucleotide sequence of the porcine LIF gene. The mRNA-synonymous strand of 2 portions of the porcine LIF gene amounting to 2.07 kbp of sequence derived from clone λ PGLIF-E2, spanning the two exons encoding the mature protein of the porcine LIF gene are listed 5' to 3' using the single letter code according to standard practice, where A refers to deoxyadenosine-5'-phosphate, C refers to deoxycytidine-5'-phosphate, G refers to deoxyguanosine-5'-phosphate and T refers to deoxythymidine-5'-phosphate. The amino acid sequence encoded by the two exons of the porcine LIF gene defined by homology with the murine, human and ovine cDNA and gene sequences (International Application No. PCT/AU88/00093) is listed above the gene sequence, where ALA is Alanine, ARG is Arginine, Asn is Asparagine, ASP is Aspartic acid, CYC is Cystein, GLN is Glutamine, GLU is Glutamic acid, GLY is Glycine, HIS is Histidine, ILE is Isoleucine, PHE is Phenylalanine, PRO is proline, SER is Serine, THR is Threonine, TRP is Tryptophan, TYR is Tyrosine, and VAL is Valine.

FIGURE 3 shows the nucleotide sequence of the ovine LIF gene. The mRNA-synonymous strand of three portions of the ovine LIF gene amounting to ~1.5 kbp of sequence derived from clone λ OGLIFR2, spanning the three protein coding regions of the ovine LIF gene are listed 5' to 3' using the single letter code according to standard practice, where A refers to deoxyadenosine-5'-phosphate, C refers to deoxycytidine-5'-phosphate, G refers to deoxyguanosine-5'-phosphate and T refers to deoxythymidine-5'-phosphate. The amino acid sequence

- 10 -

encoded by the three exons of the ovine LIF gene defined by homology with the murine and human cDNA and gene sequences (International Application No. PCT/AU88/00093) is listed above the gene sequence, where ALA is Alanine, ARG is Arginine, ASN is Asparagine, ASP is Aspartic acid, CYS is Cysteine, GLN is Glutamine, GLU is Glutamic acid, GLY is Glycine, HIS is Histidine, ILE is Isoleucine, PHE is Phenylalanine, PRO is Proline, SER is Serine, THR is Threonine, TRP is Tryptophan, TYR is Tyrosine, and VAL is Valine.

FIGURE 4 shows the amino acid sequence of porcine LIF and comparison with murine, human and ovine LIF. The amino acid sequence of murine LIF (M) as determined by direct amino acid sequencing and nucleotide sequence analysis of LIF encoding cDNAs (PCT/AU88/00093) is listed on the top line, the corresponding human and ovine amino acid sequences (H and O) determined by nucleotide sequence analysis of the human and ovine LIF genes (PCT/AU88/00093) in the middle, and the corresponding sequence of porcine LIF (P) on the bottom line. The N-terminal residue of mature murine LIF, determined by direct amino acid sequencing, is designated + 1. Identities between murine and human, between human and ovine or between ovine and porcine LIF are indicated by asterisks and conservative substitutions (Arg/Lys; Glu/Asp; Ser/Thr; Ile/Leu/Val) by dashes.

EXAMPLE 1

Identification of mammalian LIF genes by cross-hybridization with a murine LIF cDNA probe

A method has been previously disclosed (PCT/AU88/00093) for using a radioactively labelled fragment of mouse LIF cDNA as a hybridization probe to detect the human LIF gene on Southern blots. Figure 1 demonstrates that similar conditions can be used to

- 11 -

detect presumptive LIF gene homologues in a variety of mammalian DNAs, including sheep, pig, cow, guinea pig, dog, monkey, human and rat. Note that in each species, using this probe, only a unique gene is detected, with no evidence for reiterated sequences. Note also that the intensity of hybridization of the presumptive LIF gene homologues is less than that of the murine probe to rodent DNA, implying a lower degree of homology.

Each track on the gel contains 10 μ g of genomic DNA from each of the indicated species, digested to completion with the restriction endonuclease BamHI. After electrophoresis through a 0.8% w/v agarose gel and transfer to nitrocellulose using standard conditions, the immobilized DNA was hybridized with a fragment of murine LIF cDNA from clone pLIF7-2b (PCT/AU88/00093) 32p-labelled by nick-translation to a specific activity of $\sim 2 \times 10^8$ cpm/ μ g. The filter was prehybridized and hybridized at 65°C in 0.9M NaCl, 0.09 M Sodium citrate (6xSSC), 0.2% w/v Ficoll, 0.2% w/v polyvinylpyrrolidone, 0.2% w/v bovine serumalbumin, 50 μ g/ml E.coli tRNA, 0.1 mM ATP and 2 mM sodium pyrophosphate. During hybridization, 0.1% w/v SDS was included and the probe was included at $\sim 2 \times 10^7$ cpm/ml. After hybridization at 65°C for 16 hours, the filter was extensively washed in 2xSSC, 0.1% w/v SDS at 65°C and then autoradiographed using a Kodak XAR5 film and 2 screens at -70°C.

EXAMPLE 2

Isolation of the porcine LIF gene

A library of porcine genomic DNA, partially digested with Sau 3A, was screened for LIF gene-containing clones by hybridization with both a murine LIF cDNA and a portion of the human LIF gene as probes. The murine LIF cDNA fragment used as a prob corresponded to the LIF coding region and was derived from clone pLIFmut1; the human gene fragment used as a probe corresponded to the

- 12 -

3kbp BamH1 fragment spanning the human LIF gene and was derived from clone pHGLIFBam1 (PCT/AU88/00093). Conditions of hybridization were as previously disclosed (PCT/AU88/00093). Briefly, phage plaques representing the genomic library were grown at a density of 50,000 plaques per 10cm petri dish and transferred to nitrocellulose as described in Maniatis *et al.* (1982). Four nitrocellulose filters were prepared from each dish. Prior to hybridization, filters were incubated for several hours at 65°C in 6xSSC (SSC=0.15M NaCl, 0.015M sodium citrate), 0.2% w/v Ficoll; 0.2% w/v polyvinylpyrrolidone; 0.2% w/v bovine serum albumin, 2mM sodium pyrophosphate, 1mM ATP, 50µg/ml E. coli tRNA 0.1% w/v SDS at 65°C for 16-18 hours. The murine LIF cDNA and human LIF genomic DNA fragments were each radioactively labelled by nick-translation using [α -³²P] dATP to a specific activity of $\sim 2 \times 10^8$ cpm/µg or by random priming to a specific activity of $\sim 10^9$ cpm/µg and were included in the hybridization at a concentration of $\sim 2 \times 10^6$ cpm/ml. For each petri dish, 2 nitrocellulose filters were hybridized with the murine probe and two with the human probe. After hybridization, filters were extensively washed in 6xSSC, 0.1% w/v SDS at 65°C and then autoradiographed. Plaques positive on quadruplicate filters were picked and rescreened at lower density, as before. The use of two different probes simultaneously reduced the chance of identifying clones containing short sequence segments displaying fortuitous to one or other of the probes. Of the clones originally identified, one (λ PGLIF-E2) was purified. DNA from this λ clone was digested with a series of restriction endonucleases (including SalI which liberates the entire segment of cloned genomic DNA). After digestion of the recombinant phage DNAs and resolution by electrophoresis on agarose gels, the DNA was transferred to nitrocellulose and hybridized with the mouse LIF cDNA probe (under the conditions outlined above) to reveal the fragments

- 13 -

containing the LIF gene. Even after washes of higher stringency (0.2xSSC, 65°C) the porcine DNA still displayed strong hybridization with the murine probe. A 2.4kbp BamHI fragment hybridizing to the murine cDNA probe and corresponding in size to that identified in Southern blots of porcine genomic DNA was identified and subcloned into the plasmid vector pUC12, giving rise to clone pPLIFBaml.

EXAMPLE 3

10 Isolation of the Ovine LIF gene

A library of ovine genomic DNA, partially digested with Sau 3A and ligated with the lambda phage cloning vector EMBL 3A, was screened for LIF gene-containing clones by hybridization with both a murine LIF cDNA and a portion of the human LIF gene as probes. The murine LIF cDNA fragment used as a probe corresponded to the 3 kbp BAMHI fragment spanning the human LIF gene and was derived from clone pHGLIFBaml (PCT/AU88/00093). Conditions of hybridization were as disclosed in PCT/AU88/00093 and Example 2.

Of the 8 clones originally identified, one (λ OGLIFR2) was purified. DNA from this λ clone was digested with a series of restriction endonucleases (including SalI which liberates the entire segment of cloned genomic DNA). After digestion of the recombinant phage DNAs and resolution by electrophoresis on agarose gels, the DNA was transferred to nitrocellulose and hybridized with the mouse LIF cDNA probe (under the conditions outlined above) to reveal the fragments containing the LIF gene. Even after washes of higher stringency (0.2 x SSC, 65°C) the ovine DNA still displayed strong hybridization with the murine probe. A ~3 kbp BamHI fragment hybridizing to the murine cDNA probe was identified and subcloned into the plasmid vector pEMBL8+, giving rise to clone pOGLIFBaml.

- 14 -

EXAMPLE 4

Determination of nucleotide and amino acid sequences of the porcine and ovine LIF.

Nucleotide sequencing was performed by the dideoxy
5 chain termination method (Sanger et al, 1977) using the
SEQUENASE (registered trade mark) reagents and protocol
(United States Biochemicals). The nucleotide sequences
of porcine and ovine LIF DNA are shown in Figures 2 and
3. Templates were single-stranded DNA of various
10 fragments derived from the 2.4kbp BamHI fragment of
pPLIFBamI or the 3kbp BamHI fragment of pOGLIFBamI
subcloned into M13 phage vectors (Messing and Vieira
1982). The primers used were both an external primer in
the M13 sequence and a variety of oligonucleotides
15 complementary to sequences within the gene.

The porcine and ovine LIF sequences thus determined
are shown in Figures 2 and 3, respectively. Alignment of
these sequences with the human and mouse gene sequences
20 reveal that they contain coding regions specifying
proteins highly homologous to murine and human LIF. The
protein sequence encoded by these coding regions are
listed above the nucleotide sequences.

25 The complete amino acid sequence of porcine and
ovine LIF are aligned with the murine and human LIF
sequences in Figure 4 with identities indicated by
asterisks and conservative substitutions by dashes. Many
large blocks of amino acid sequence remain totally
30 conserved between all four species. However, it is
evident that the porcine sequence is more closely related
to the ovine than the human and murine sequence. A
comparison of each of these four LIF sequences is
presented in Table 1, in which only the mature portion of
35 the LIF molecule is considered, excluding the hydrophobic
leader. Only identities are scored in this comparison.

- 15 -

TABLE 1

Comparison of LIF amino acid sequences
(Percent Identity)

5		<u>MURINE</u>	<u>HUMAN</u>	<u>OVINE</u>	<u>PORCINE</u>
	MURINE:	100	78	74	77
	HUMAN:		100	88	85
	OVINE:			100	83
	PORCINE:				100
10					

The methods disclosed in PCT/AU88/00093 can be used for the construction of a variety of expression vectors carrying the livestock (eg ovine or porcine) LIF gene.

15 Such vectors include yeast (e.g. YEpsecl, Baldari et al, 1987), and E.coli e.g., vector pGEX-2T, Smith and Johnson, 1988Gearing et al, 1989;). Conditions for expression are as disclosed in PCT/AU88/00093.

20

EXAMPLE 5

The enhancement of the development of 8 cell murine embryos by addition of LIF is described in the following example, which is included by way of illustration and not

25 limitation of the present invention.

1. MATERIALS AND METHODS

Animals

30

Balb-C x C57 three to four weeks old F1 female mice were primed with 7.5 iu PMSG (Folligon; Intervet, Australia) followed 48 hours later, with 7.5 iu hCG (Chorulon; Intervet, Australia) to achieve

35 superovulation. Immediately following the hCG (Human chorionic Gonadotrophin) injection, treated females were placed with fertile males (CBA C57 strain, one female

- 16 -

plus one male per cage). The next morning each female was checked for the presence of a vaginal plug as evidence of mating. This was then considered as Day 1 of pregnancy.

5

Media

The culture medium was prepared from powdered Minimal Essential Medium (MEM; Eagle, with Earle's salts, with L-glutamine without sodium bicarbonate; Flow Laboratories, UK) dissolved in Milli-Q water and supplemented with 1 µg/ml glucose, 25 mM sodium bicarbonate and 10% (v/v) heat-inactivated fetal calf serum (FCS; CSL, Australia). An antibiotic/antimycotic solution was also added to provide per 100 ml of solution, 10,000 units penicillin, 10,000 µg streptomycin and 25 µg fungizone (CSL, Australia). The pH and osmolarity of the media were adjusted to 7.40 and 280 mOsm respectively. At this point the media was sterilised by filtration (Acrodisc 0.2 µm filter; Gelman Sciences Inc., USA).

Embryos

On Day 3 of pregnancy females were killed between 1300-1500 hours, i.e. 71-73 hours post-hCG injection, by cervical dislocation. The whole reproductive tract was dissected out and placed in Earle's Balanced Salt Solution without Calcium and Magnesium (EBS9) at 37°C. Subsequently, 8-cell embryos were teased/flushed out of the oviduct-uterus junction and after washing once in culture medium were placed into control or experimental group (see below) and maintained in a humidified gas environment of 5% CO₂ in air, at 37°C.

35

- 17 -

Culture of Embryos

For experimentation, 8-cell embryos were randomly assigned to a control or experimental group with each group consisting of eight replicates with embryos from four to six mice used per replicate. Embryos were added 10-20 per well approximately 15-20 minutes after recovery from the uterus and maintained in vitro for a period of five days in wells containing the culture media alone (1ml/well) or the culture media with LIF (1000 u/ml) supplementation as indicated. This dosage of LIF was chosen as it is optimal for the inhibition of differentiation of ES cells (International Patent Application No. PCT/AU89/00330).

Assessment of Morphological Development

Observations on embryo development were made daily using an inverted microscope and the numbers of embryos achieving morula, blastocyst or hatching blastocyst stage recorded (Hsu, 1979). On Days 4-5 of culture, many embryos underwent developmental changes associated with implantation (Sherman, 1978). For this study, post hatching embryos were recorded as achieving stage 1 when they displayed proliferating trophectoderm cells, and stage 2 when they showed outgrowth of trophectoderm cells.

2. RESULTS

30

The effect on the development of the mouse 8-cell embryos in vitro of including LIF (10^3 units/ml in culture medium, prior, to (PRE) or following (POST) formation of the blastocysts are shown in Table 2. The results are expressed as % initial number of embryos (n=35) completing the developmental stage.

- 18 -

Table 2

		<u>LIF</u>	8-cell → BLASTOCYST → IMPLANTATION	
5	PRE	POST		
	*-	-	100	57.6
	+	-	100	67.2
	-	+	100	85.7
10	+	+	99	77.2

Control only

- 15 By combining data on all experiments where LIF (10^3 units/ml) has been added to the culture medium, a definite effect has been found where the addition of LIF enhances the development of 8 cell mouse embryos to the implantation stage 2 (see Materials and Methods -
- 20 Assessment of Morphological Development) as follows:

	Control	LIF
<u>Embryos to Implantation Stage 2 =</u>	<u>226</u>	<u>156</u>
Total No. 8-cell Embryos Cultured	349	195
25	(64%)	(80%)
$(\chi^2 = 27.0 \text{ } P \leq 0.001)$		

- Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

EXAMPLE 6

5

Expression of ovine LIF

A contiguous coding region for ovine LIF was constructed by intron removal and site directed mutagenesis in a manner analogous to the human LIF gene as previously described.

The ovine LIF coding region so constructed was cloned into yeast expression vector YEpsec-1 in the correct (clones 3 and 15) and incorrect (clone 5) orientation. LIF activity was determined and the results are shown in Table 3. LIF activity is expressed as Units/ml as determined using the M1 cell differentiation bioassay as described before. The mouse positive control (mouse +ve) is a yeast clone containing YEpsec-1 with the murine LIF gene inserted in the correct orientation.

Table 3

25

Yeast Clone	LIF Activity (Units) (Units/ml)
<hr/>	
Clone 3	10,700
Clone 15	829,000
Clone 5	0
mouse +ve	61,400

35

- 20 -

EXAMPLE 7

Receptor Binding Competition Assay

5 The receptor binding competition assay was performed as previously described. The assay shows the ability of yeast derived sheep LIF to compete with iodinated murine LIF for binding to specific cellular receptors on mouse
10 liver cells.

Table 4

15 Competitor	[](ng/ml)	¹²⁵ I.LIF Specifically bound cpm
20 pure rec. human (E.coli)	10000	0
	1000	323
	100	575
	10	258
	1	1053
	0.1	1279
	0.01	1600
25 pure rec human LIF (yeast)	100	614
	1	1078
crude sheep LIF (yeast)	1:1	625
	1:10	822
30 Saline	-	2549
	untransf. yeast medium 1:1	2603
	1:10	2591

35

REFERENCES CITED

- Baldari et al. EMBO J 6: 229-234, 1987
- Hsu Y-C, Developmental Biology 68 4530616, 1979
- 5 Maniatis et al. Molecular Cloning. A Laboratory Manual.
Cold Spring Harbor Laboratory, Cold Spring Harbor USA
1982
- Messing and Vieira, Gene 19: 269-276, 1982
- Sanger et al. Proc. Natl. Acad. Sci. USA 74: 5463-5462,
10 1977
- Sherman, Methods in Mammalian Reproduction, New York:
Academic Press pp 81-125, 1978
- Smith and Johnson Gene 67: 31-40, 1988
- Gearing, Nicola, Metcalf, Foote, Willson, Gough and
15 Williams Biotechnology 7: 1157-1161, 1989

- 22 -

CLAIMS

1. A first nucleic acid molecule encoding a livestock species leukaemia inhibitory factor comprising a nucleotide sequence capable of hybridizing to a second nucleic acid molecule which encodes murine leukaemia inhibitory factor or part thereof.
2. The first nucleic acid molecule according to claim 1 wherein said nucleic acid is single or double stranded DNA.
3. The first nucleic acid molecule according to claim 1 wherein said nucleic acid is RNA.
4. The first nucleic acid molecule according to any one of claims 1 to 3 wherein said livestock species is a sheep, pig, goat, cow, horse or donkey.
5. The first nucleic acid molecule according to claim 4 wherein said livestock species is a sheep or pig.
6. A recombinant DNA molecule comprising a replicable vector and the first nucleic acid according to any one of the proceeding claims inserted therein operably linked to a regulatory region capable of directing the expression of said first nucleic acid molecule.
7. The recombinant DNA molecule according to claim 6 wherein said molecule is capable of replicating in a prokaryotic and/or a eukaryotic cell.
8. The recombinant DNA molecule according to claim 7 wherein said prokaryotic cell is Escherichia coli and said eukaryotic cell is a yeast.

- 23 -

9. A host cell carrying the recombinant DNA molecule according to any one of claims 6 to 8.
- 5 10. Recombinant LIF or parts thereof encoded by the first nucleic acid according to any one of claims 1 to 5.
- 10 11. A method for enhancing the in vitro development of a mammalian embryo to the implantation stage which method comprises the step of culturing the embryo in vitro in a culture medium containing an effective amount of mammalian LIF and for a time and under conditions sufficient to enhance the development of an embryo to implantation stage.
- 15 12. The method according to claim 11 wherein the mammalian embryo is of human, murine or livestock animal origin.
- 20 13. The method according to claim 12 wherein the mammalian embryo is isolated from a livestock species.
- 25 14. The method according to claim 11 wherein the mammalian LIF is from human, mouse or livestock species.
- 30 15. The method according to claim 14 wherein the mammalian LIF is from livestock species.
- 35 16. The method according to claim 15 wherein the livestock species is a sheep, pig, goat, cow, horse or donkey.
17. The method according to claim 16 wherein the livestock species is a sheep or a pig.

- 24 -


18. A method for in vitro fertilization and subsequent
implantation of a mammalian embryo which is
characterised in that the embryo is cultured in
vitro in a culture medium containing an effective
amount of mammalian LIF prior to implantation.
19. The method according to claim 18 wherein said
mammalian LIF is human, murine or from a livestock
species.
20. The method according to claim 19 wherein said
livestock species is sheep, pig, goat, cow, horse or
donkey.
21. A method for maintaining ES cell lines in in vitro
culture while retaining a pluripotential phenotype
which method comprises contacting said ES cell lines
with an ES cell line maintaining effective amount of
livestock species LIF for sufficient time and under
appropriate conditions.
22. The method according to claim 21 wherein the
livestock species is a sheep, pig, goat, cow, horse
or donkey.
23. The method according to claim 22 wherein the
livestock species is a sheep or pig.

9 January, 1990

1/12

Cross-species hybridization with a
mouse LIF probe

Sheep
Pig
Cow
Guinea Pig
Dog
Monkey
Human
Rat
Mouse



Wash: 2xSSC, 65 C

Fig. 1.

2/12

<i>Fig.2a.</i>	<i>Fig.2b.</i>	<i>Fig.2c.</i>
----------------	----------------	----------------

Fig.2.

<i>Fig.3a.</i>	<i>Fig.3b.</i>	<i>Fig.3c.</i>
----------------	----------------	----------------

Fig.3.

<i>Fig.4a.</i>	<i>Fig.4b.</i>
<i>Fig.4c.</i>	<i>Fig.4d.</i>

Fig.4.

3/12

GATCCCCACAGAGCTG--GGACAGGAAGTTTTGA
AGTGAGCGGCCACAGTGGGGGAAGGAGAAACACA
CTTGGGAGATGAGGGTGAGCAGAACCCCTCCCC
ATCCTGGGAGGTGGGGAGATAGGGTCAGCTCTTC
CCTGGACCCAGCTTCTCTACTGGTACAAATAGCTC
AGGTGGTGACATCGTCAGGGCTGGGGAAGAGAGA

CCTTGCCTACCCCTTTCACCTCCCTAATCATGGCT
SerProLeuSerIleThrProValAsnAlaThrC
AGCCCCCTTTCATCACTCCTGTCAATGCCACCT
snSerSerAlaAsnAlaLeuPheIleLeuTyr
ACAGCAGTGCCAACGCCCTCTTTATTCTCTACGT
TGCTGTGGGACCTGGGCTGGCGGGCTGGCTAGGG
CCTGGCCAAGGCTCGGTCACTTTCCCCGGGGGCC
CACCTCTGGAGCAAGAGGCACATGAGAGGAGAGA

.....
GTCCCAAGCTGCCTTGGGGCAATTGAGTGGGTCA

GGGAAGCCCTGTCCCTGACTCCATGTCACCTCCC
CysGlyProAsnValThrAsnPheProProPheH
TGTGGCCCCAACGTGACCAACTTCCCGCCCTTCC
erLeuGlyAsnIleThrArgAspGlnArgSerLe
CCCTGGGCAACATCACGCGGGACCAAAGGAGCCT
uSerAsnValLeuCysArgLeuCysAsnLysTyr
CAGCAATGTGCTCTGCCGCTGTGCAACAAGTAC
LysLeuGlyCysGlnLeuLeuGlyLysTyrLysG
AAGCTGGGCTGTCAGCTCCTGGGGAAGTATAAGC
TTAGACTTAGGTGACTCTCAAAGTGTGCCGGGGC
CTGTCTCCTCTCCTCAGGGGTGGGCTGTGATGAA
CCAGGCATTGGTGTGGGCTGCCCCCTCCACCAT

Fig.2a.

4/12

```

GGGATT-TTTGGTCAAGGAGAGGGGAATTGCAGA
GAGAAGATGGGCAAAGGAGATGGAATTAGGGGAC
CCTTCCCCATGGTCCCAGCTCGCTCTGGGAGACT
TCTCTGTGACCTGCTGGGCTTGGGGTGTGGTGCC
CTTTCCTGCCCCCTTGCTACCAGAGGTAGAGAGTT
GCTGGAGGCTGAGAGGGGACACTGGTGTCCCTAA
                                GlyValValProLeuL
CGTTTTTGCCTGTTTGCAGGAGTTGTGCCCCCTGC
ysAlaThrArgHisProCysHisSerAsnLeuMe
GTGCCACACGTCACCCATGTCACAGCAACCTCAT

AAGTTCACCCCCCTTGCCCCGACCCAGGGTGCTG
AAGGGAAGGGAGGGGGGCTCGGTCTTACCATGTG
CTGTTACATATTGGCAGAGCTGCCTGGAGGCGGG
AGGAGG.....
.....GATCCTCCGCACGGCCCGGGTGTGCGTT
TCGTGCCAGTTTGGGGGCAGTGGGGACCTGAGGC
                                TyrThrAlaGlnG
CTCTGTGCCTCTGCCCCCTCAGTACACAGCCCAGG
isAlaAsnGlyThrGluLysAlaArgLeuValGI
ACGCCAACGGCACCGAGAAGGCCCGGCTGGTGGA
uAsnProGlyAlaValAsnLeuHisSerLysLeu
CAATCCTGGTGCTGTGAACCTGCACTCCAAGCTG
HisValAlaHisValAspValAlaTyrGlyProA
CACGTGGCCCATGTGGATGTGGCCTACGGCCCCG
InValIleSerValLeuAlaArgAlaPhe***
AGGTCATCTCTGTGCTAGCCCGGGCCTTCTGATG
CCAGAACATCACCAGACCCAAGTGGGGGTGCTG
GCAGAACCCAAACTCCCGGAGGCAGAACCAACTA
CACCACCTTGTTCCCTCAGTCAGAGTCTTCATGA

```

Fig.2b.

5/12

ATTGGGGTGGAGTTGAGGGTCCTAGATAGGGG	100
GAATGGTCAGTGAGCCAAAATCATGTGCTAGG	200
CAGGTATGAAGTAACACTTAAGAATTTGGACC	300
CTCCAGCCAAAGGCCAGGATGGTTGTTGTCAC	400
AGCCATCTGGAGAGAGGGGAGATAGAGGAGGAG	500
AGGAGACGAGGGCGCATCCTATCCTGGGAGCCC	600
euLeuValLeuHisTrpLysHisGlyAlaGly	
TGCTGGTTCTGCACTGGAAACACGGGGCAGGG	700
tAsnGlnIleLysAsnGlnLeuAlaHisValA	
GAACCAGATCAAGAACCAGCTGGCGCACGTCA	800
AGGAAGGAAGGAGGGAGGGAGGGGCTGGGGTT	900
CAGAGTCCCACAGCTTCCGCCCCACTCCCCAC	1000
GAGGCCTGACACTTCGAGCCTCAGGCTTCCTC	1100
..... - 0.2 kbp	
CACACCCACAGTTACTTCTGGTTCTCAGGACG	1200
CAAGACCTGACCCAGAGGCTTGGAGGCAGCGC	1300
lyGluProPheProAsnAsnLeuAspLysLeu	
GGGAGCCATTTCCTCAACAACCTTGGACAAGCTG	1400
uLeuTyrArgIleIleAlaTyrLeuGlyAlaS	
GCTGTACCGCATCATCGCCTACCTTGGCGCCT	1500
AsnAlaThrAlaAspSerMetArgGlyLeuLe	
AACGCCACGGCGGACAGCATGCGAGGCCTCCT	1600
spThrSerGlyLysAspValPheGlnLysLys	
ACACCTCGGGCAAGGACGTCTTCCAGAAGAAG	1700
GAAGGTCCCCTAGCACCCCGTGACCTGAGGTC	1800
ACAGACCCGGGAGGGAGGGGGG---TTCTTAG	1900
GAGAAGGCATCCCTTGTCTGGGAGACTGCAG	2000
TC	2070

Fig.2c.

6/12

GATCCCGGCTAAATATAGCTGTTTCTCTGTCTTA
GGCATCTGAGGTCTCGTCCAAGGTCTCTGGAGC
.....
CTGCCCAGGGAAGACAGAGGGGGGTCAGGGAGTC
GlyValValProLeuLeuLeuVa
GCCTCTCCCCAGGAGTCGTGCCCTGCTGCTGGT
rHisHisProCysProSerAsnLeuMetSerGln
ACACCACCCATGCCCCAGCAACCTCATGAGCCAG
CCCCCAGGGGACAAGAAGGGAGGGAGGGCCCCGGG
TGTCTCGGGGAGGGGGGGGAGTGTTGGGGGGGAC
AGGCAAGACACCACATTTTCCTTTCTGTCCCCGT
.....
GGCGTTGGGTCTCTCGTGCTATGGGTGGGCACACT
TCCTGGGGTCACCTACCTTCCGTCCCTCTACTCC
rAspPheProProPheGlnProAsnGlyThrGlu
GGACTTCCCGCCCTTCCAGCCCCAACGGCACGGAG
ArgAspGlnLysThrLeuAsnProThrAlaHisS
CGGGACCAGAAGACCCTCAACCCACGGCGCACA
rgLeuCysSerLysTyrHisValAlaHisValAs
GCCTGTGCAGCAAGTACCACGTGGCCCCACGTGGA
uLeuGlyLysTyrLysGlnValMetAlaValLeu
GCTGGGAAAATACAAGCAGGTCATGGCCGTGTTG

Fig. 3a.

7/12

```

CAACACAGGCTCCAGTATATAAATCCGGCAAA
      MetLysIleLeuAlaAla
ACACAGCCCATGATGAAGATCTTGGCGGCAGG
-1.5 kbp .....
CCTCCCCTGGCATCCAGTGTGACCCCCAAGC
lLeuHisTrpLysProGlyAlaGlySerProL
CTTGCACTGGAAACCCGGGGCGGGGAGCCCC
IleArgSerGlnLeuAlaGlnLeuAsnGlyTh
ATCAGGAGCCAGCTGGCACAGCTCAATGGCAC
AGGAGGGGGCGAGGAACAGAAACCAGGCAGCAG
GCCCAGGAAGAAGGTGAGGGCAGTGGGTGAAA
GTCGTCCTC.....
.....TCGCACCTACCACGCTGCTGCTG
GAGCACCTCCAGCTCCTGCCCCAGGAGCTGG
      TyrThrAlaGlnGlyGluProPheProA
TCAGTACACAGCCCAAGGGGAGCCGTTCCCCA
LysValArgLeuValGluLeuTyrArgIleVa
AAGGTCAGGCTGGTGGAGCTGTACCGCATCGT
erLeuHisSerLysLeuAsnAlaThrAlaAsp
GCCTGCACAGCAAACCTCAACGCCACGGCGGAC
pValAlaTyrGlyProAspThrSerGlyLysA
CGTGGCCTATGGCCCCGGACACCTCGGGCAAGG
AlaGlnAlaPhe***
GCGCAGGCCTTCTAGGTGGCCGGCCGTGAACT

```

Fig.3b.

8/12

```

TTCCCCATTTGAGCATGAACCTCTGAAAACGGCC
TAAAT.....
.....AGATGCTGAGACAAAGTGAAAACCCACC
ACCCGTCCACCTCTGCGCTCACGGCTCCTCCT
euProIleAsnProValAsnAlaThrCysAsnTh
TTCCCATCAACCCCGTCAACGCCACCTGCAACAC
rAlaAsnAlaLeuPheIleLeuTyr
TGCCAACGCCCTCTTTATTCTCTATGTAAGTTAA
GCAGACAGGAAGGTGCTGCCGAGAGGGCTGTGGG
GTGCAAGTGTGTGGTGCGCCCCGCCGAGGGCAGAC
0.2kbp .....
GTTCCACAGCCAGTTCTAGCTGTCTCCAGGGCAA
CTGGAGGCAGGGCCGGAACACTGCCCCCCTGAC
snAsnLeuAspLysLeuCysGlyProAsnValTh
ACAACCTGGACAAGCTGTGCGGCCCCAATGTGAC
lAlaTyrLeuGlyThrAlaLeuGlyAsnIleThr
GGCCTACCTTGGCACCGCCCTGGGCAACATCACC
ThrLeuArgGlyLeuLeuSerAsnValLeuCysA
ACGCTGCGGGGCTGCTTAGCAACGTGCTGTGCC
spValPheGlnLysLysLysLeuGlyCysGlnLe
ACGTCTTCAGAAGAAGAAGCTGGGGTGTGAGCT
GATGGGTCC CAGGAGGGGATCC

```

Fig.3c.

9/12

```

M: MetLysValLeuAlaAlaGlyIleValProLeuLeuValLeuLeuHisTrpLysHis
  *****_-----
H: MetLysValLeuAlaAlaGlyValValPro
  *****_-----
O: MetLysIleLeuAlaAlaGlyValValPro
  *****
P:      GlyValValPro      LeuLeuValLeuHisTrpLysHis

M: CysHisGlyAsnLeuMetAsnGlnIleLysAsnGlnLeuAlaGlnLeuAsnGlySerAla
  *****_-----
H: CysHisAsnAsnLeuMetAsnGlnIleArgSerGlnLeuAlaGlnLeuAsnGlySerAla
  *****_-----
O: CysProSerAsnLeuMetSerGlnIleArgSerGlnLeuAlaGlnLeuAsnGlyThrAla
  *****_-----
P: CysHisSerAsnLeuMetAsnGlnIleLysAsnGlnLeuAlaHisValAsnSerSerAla

M: LysLeuCysGlyProAsnMetThrAspPheProSerPheHisGlyAsnGlyThrGluLys
  *****
H: LysLeuCysGlyProAsnValThrAspPheProProPheHisAlaAsnGlyThrGluLys
  *****
O: LysLeuCysGlyProAsnValThrAspPheProProPheGlnProAsnGlyThrGluLys
  *****
P: LysLeuCysGlyProAsnValThrAsnPheProProPheHisAlaAsnGlyThrGluLys
  *****

```

Fig.4a.

10/12

```

+1
GlyAlaGlySerProLeuProIleThrProValAsnAlaThrCysAlaIleArgHisPro
*****
GlyAlaGlySerProLeuProIleThrProValAsnAlaThrCysAlaIleArgHisPro
*****
GlyAlaGlySerProLeuProIleAsnProValAsnAlaThrCysAsnThrHisHisPro
*****
GlyAlaGlySerProLeuSerIleThrProValAsnAlaThrCysAlaThrArgHisPro
*****

AsnAlaLeuPheIleSerTyrTyrThrAlaGlnGlyGluProPheProAsnAsnValGlu
*****
AsnAlaLeuPheIleLeuTyrTyrThrAlaGlnGlyGluProPheProAsnAsnLeuAsp
*****
AsnAlaLeuPheIleLeuTyrTyrThrAlaGlnGlyGluProPheProAsnAsnLeuAsp
*****
AsnAlaLeuPheIleLeuTyrTyrThrAlaGlnGlyGluProPheProAsnAsnLeuAsp
*****

ThrLysLeuValGluLeuTyrArgMetValAlaTyrLeuSerAlaSerLeuThrAsnIle
*****
AlaLysLeuValGluLeuTyrArgIleValValTyrLeuGlyThrSerLeuGlyAsnIle
-----
ValArgLeuValGluLeuTyrArgIleValAlaTyrLeuGlyThrAlaLeuGlyAsnIle
*****
AlaArgLeuValGluLeuTyrArgIleIleAlaTyrLeuGlyAlaSerLeuGlyAsnIle
-----

```

Fig.4b.

11/12

M: ThrArgAspGlnLysValLeuAsnProThrAlaValSerLeuGlnValLysLeuAsnAla

 H: ThrArgAspGlnLysIleLeuAsnProSerAlaLeuSerLeuHisSerLysLeuAsnAla

 O: ThrArgAspGlnLysThrLeuAsnProThrAlaHisSerLeuHisSerLysLeuAsnAla

 P: ThrArgAspGlnArgSerLeuAsnProGlyAlaValAsnLeuHisSerLysLeuAsnAla

M: ArgValGlyHisValAspValProProValProAspHisSerAspLysGluAlaPheGln

 H: HisValGlyHisValAspValThrTyrglyProAspThrSerGlyLysAspValPheGln

 O: HisValAlaHisValAspValAlaTyrGlyProAspThrSerGlyLysAspValPheGln

 P: HisValAlaHisValAspValAlaTyrGlyProAspThrSerGlyLysAspValPheGln

M: GlnAlaPhe

 H: GlnAlaPhe

 O: GlnAlaPhe

 P: ArgAlaPhe

Fig.4c.

12/12

```

ThrIleAspValMetArgGlyLeuLeuSerAsnValLeuCysArgLeuCysAsnLysTyr
***  ***---  ***
ThrAlaAspIleLeuArgGlyLeuLeuSerAsnValLeuCysArgLeuCysSerLysTyr
***  ***  ***
ThrAlaAspThrLeuArgGlyLeuLeuSerAsnValLeuCysArgLeuCysSerLysTyr
***  ***---  ***
ThrAlaAspSerMetArgGlyLeuLeuSerAsnValLeuCysArgLeuCysAsnLysTyr

```

```

ArgLysLysLeuGlyCysGlnLeuLeuGlyThrTyrLysGlnValIleSerValValVal
---  ***
LysLysLysLeuGlyCysGlnLeuLeuGlyLysTyrLysGlnIleIleAlaValLeuAla
***  ***
LysLysLysLeuGlyCysGlnLeuLeuGlyLysTyrLysGlnValMetAlaValLeuAla
***  ***
LysLysLysLeuGlyCysGlnLeuLeuGlyLysTyrLysGlnValIleSerValLeuAla

```

Fig.4d.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/AU 90/00001

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) 6

According to International Patent Classification (IPC) or to both National Classification and IPC

Int. Cl.⁵ C12N 15/19; C07H 21/04, 21/02; C12N 5/02, 5/06, 5/08

II. FIELDS SEARCHED

Minimum Documentation Searched 7

Classification System |

Classification Symbols

IPC

WPI, WPIL, USPA, Chem Abstracts: keyword: leukemia or leukaemia or leucemia or leucaemia and inhibit: and factor or protein or polypeptide

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched 8

ORBIT BIOT: Keywords as above

Genbank, EMBL, NERF, Swiss-Prot : DNA, amino acid sequences : AU search: C12N 15/19 (all years); C12N 5/02, 5/06, 5/08, 5/00 (1987-1990)

III. DOCUMENTS CONSIDERED TO BE RELEVANT 9

Category*	Citation of Document, with indication, where appropriate, of the relevant passages 12	Relevant to Claim No 13
X	Nature 336 (6200): 684-7 (1988), Williams R.L. et al, "Myeloid leukemia inhibitory factor maintains the development potential of embryonic stem cells"	11, 12, 14
A	Biotechnology 7(11): 1157-61 (1989), Gearing D.P. et al, "Production of leukemia inhibitory factor in E. coli by a novel procedure and its use in maintaining embryonic stem cells in culture"	1-23
A	Nature 336 (6200): 690-2 (1988), Moreau J.F. et al, "Leukemia inhibiting factor is identical to the myeloid growth factor human interleukin for DA cells"	1-10, 21-23

(continued)

* Special categories of cited documents: 10

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&"

document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

19 April 1990 (19.04.90)

Date of Mailing of this International Search Report

24 April 1990

International Searching Authority

Australian Patent Office

Signature of Authorized Officer

R. SAWYER

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category*	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
A	P.N.A.S 85(8): 2623-27 (1988), Gough N.M. et al, "Molecular cloning and expression of the human homologue of the murine gene encoding myeloid leukemia inhibitory factor"	1-10
A	EMBO J. 6 (13): 3995-4002 (1987), Gearing D.P et al, "Molecular cloning and expression of cDNA encoding a murine myeloid leukemia inhibitory factor (LIF)"	1-10
A	AU-A-15907/88 (Amrad Corporation) 2 November 1988 (02.11.88)	1-10, 21-23

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON
INTERNATIONAL APPLICATION NO. PCT/AU 90/00001

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Members			
<hr/>					
AU 15907/88	DK 4831/89	FI 894613	NO 885339		
	WO 8807548	EP 285448	IL 85961		
	PT 87133	ZA 8802277			

END OF ANNEX